Pathway to care for drug resistant tuberculosis cases identified during a retrospective study conducted in high TB burden wards in Mumbai.
Eunice LoboShimoni ShahSheela RanganYatin DholakiaNerges MistryPublished in: Gates open research (2018)
Background: Mumbai is witnessing a rising incidence of all forms of drug resistant tuberculosis (DR-TB). Methods: A population-based, retrospective study was conducted between April and July 2014, in 15 high TB burden wards in Mumbai, to capture the patient pathways to TB care. A total of 23 DR-TB patients were identified and their pathways to access DR-TB care were recorded using semi-structured interviews. Results: The total DR-TB pathway time of new patients (who did not report any past episode of TB) (180 days; IQR 123,346) was found to be more than twice that of retreatment patients (who reported a past episode of TB) (69 days; IQR 42,128). Conclusions: The unacceptable delay for diagnosis and treatment of DR-TB in Mumbai advocates for consistent implementation of early screening of patients using rapid gene-based technologies.
Keyphrases
- mycobacterium tuberculosis
- drug resistant
- healthcare
- multidrug resistant
- end stage renal disease
- editorial comment
- ejection fraction
- pulmonary tuberculosis
- acinetobacter baumannii
- newly diagnosed
- palliative care
- prognostic factors
- risk factors
- pain management
- peritoneal dialysis
- pseudomonas aeruginosa
- dna methylation
- cystic fibrosis
- genome wide
- human immunodeficiency virus
- transcription factor
- copy number
- quantum dots
- sensitive detection
- hiv infected